Abstract:Chronic inflammation triggers development of metabolic disease, and pulmonary tuberculosis (TB) generates chronic systemic inflammation. Whether TB induced-inflammation impacts metabolic organs and leads to metabolic disorder is ill defined. The liver is the master regulator of metabolism and to determine the impact of pulmonary TB on this organ we undertook an unbiased mRNA and protein analyses of the liver in mice with TB and reanalysed published data on human disease. Pulmonary TB led to upregulation of genes in the liver related to immune signalling and downregulation of genes encoding metabolic processes. In liver, IFN signalling pathway genes were upregulated and this was reflected in increased biochemical evidence of IFN signalling, including nuclear location of phosphorylated Stat-1 in hepatocytes. The liver also exhibited reduced expression of genes encoding the gluconeogenesis rate-limiting enzymes Pck1 and G6pc. Phosphorylation of CREB, a transcription factor controlling gluconeogenesis was drastically reduced in the livers of mice with pulmonary TB as was phosphorylation of other glucose metabolism-related kinases, including GSK3a, AMPK, and p42. In support of the upregulated IFN signalling being linked to the downregulated metabolic functions in the liver, we found suppression of gluconeogenic gene expression and reduced CREB phosphorylation in hepatocyte cell lines treated with interferons. The impact of reduced gluconeogenic gene expression in the liver was seen when infected mice were less able to convert pyruvate, a gluconeogenesis substrate, to the same extent as uninfected mice. Infected mice also showed evidence of reduced systemic and hepatic insulin sensitivity. Similarly, in humans with TB, we found that changes in a metabolite-based signature of insulin resistance correlates temporally with successful treatment of active TB and with progression to active TB following exposure. These data support the hypothesis that TB drives interferon-mediated alteration of hepatic metabolism resulting in reduced gluconeogenesis and drives systemic reduction of insulin sensitivity. Tuberculosis (TB) is a worldwide disease with a substantial proportion of undiagnosed cases. Control of TB is mediated by a protective cellular immune response which is also chronic, inflammatory and systemic. Chronic inflammation can disrupt metabolism and compromise the organs key to maintaining health–such as the liver. The extent to which pulmonary TB can disrupt the metabolic function of the liver is ill defined. We have used a mouse model of pulmonary TB to examine the changes occurring in the liver when immunity is first being expressed in the lung. We found that pulmonary TB leads to upregulation of immune-related signalling pathways in liver cells and that TB infected mice have altered glucose metabolism. Reanalysing published metabolic data from humans, we find that a metabolic signature associated with insulin resistance separates those with TB from healthy subjects and alters with time to progression and resolution of TB, thereby indicating glucose metabolism disruption occurs during TB in humans. These data are important because we show that TB disrupts liver glucose metabolism, and this is critical to understanding the interplay between TB and metabolic disease.

PPARγ mediated enhanced lipid biogenesis fuels growth in a drug-tolerant hepatocyte environment.

Altered hepatic metabolic landscape and insulin sensitivity in response to pulmonary tuberculosis

Metabolic Versatility of Mycobacterium tuberculosis during Infection and Dormancy

Lipid Peroxidation and Type I Interferon Coupling Fuels Pathogenic Macrophage Activation Causing Tuberculosis Susceptibility

Mycobacterium Tuberculosis Carrying a Rifampicin Drug Resistance Mutation Reprograms Macrophage Metabolism Through Cell Wall Lipid Changes

Mycobacterium Tuberculosis Enhances Macrophage P-glycoprotein (MDR-1) Expression and Activity to Promote Intracellular Survival

Impaired fatty acid import or catabolism in macrophages restricts intracellular growth of Mycobacterium tuberculosis

Lung infection perturbs metabolic pathways in non-pulmonary tissues

Fatty acid metabolism in neutrophils promotes lung damage and bacterial replication during tuberculosis

MicroRNA-144-3p Inhibits Host Lipid Catabolism and Autophagy by Targeting PPARα and ABCA1 During Mycobacterium Tuberculosis Infection

Compromised Metabolic Reprogramming Is an Early Indicator of CD8+ T Cell Dysfunction during Chronic Mycobacterium tuberculosis Infection

Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve control in infected mice

Phosphoglucomutase A mediated regulation of carbon flux is essential for antibiotic and disease persistence in Mycobacterium tuberculosis

The pathogenic mechanism of Mycobacterium tuberculosis: implication for new drug development

Immune Responses to Mycobacterium tuberculosis Infection in the Liver of Diabetic Mice

A terpene nucleoside from M. tuberculosis induces lysosomal lipid storage in foamy macrophages

Small Molecule Targeting PPM1A Activates Autophagy for Mycobacterium tuberculosis Host-Directed Therapy

Bile acids, lipid and purine metabolism involved in hepatotoxicity of first-line anti-tuberculosis drugs

Infection with Mycobacterium tuberculosis induces the Warburg effect in mouse lungs

The impact of Mycobacterium tuberculosis on the macrophage cholesterol metabolism pathway

Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review